BA-210 BioAxone BioSciences, Inc. has a  patent portfolio protecting BA-210.

BA-1049 and other Rho Kinase 2-selective  Inhibitors: BioAxone holds an issued patent on novel small molecule Rho kinase inhibitors. The company has a portfolio of issued and pending applications for the ROCK2-selective inhibitors that are in development for angioma, stroke and glaucoma.

BA-43407- BioAxone has filed a composition of matter patent on a self-delivering RNAi molecule that targets PTEN.